Cite
HARVARD Citation
Porcu, P. et al. (n.d.). Quality of life in cutaneous T cell lymphoma patients treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from MAVORIC. European journal of cancer. pp. S38-S39. [Online].